Format

Send to

Choose Destination
See comment in PubMed Commons below
Mol Cancer Ther. 2016 Oct;15(10):2399-2412. Epub 2016 Sep 14.

Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells.

Author information

1
Cell Biology and Pharmacogenomics Department, Pharmamar SA, Colmenar Viejo, Madrid, Spain.
2
Department of Functional Genomics and Cancer, IGBMC, CNRS/INSERM/University of Strasbourg, C. U. Strasbourg, France.
3
Cell Biology and Pharmacogenomics Department, Pharmamar SA, Colmenar Viejo, Madrid, Spain. cgalmarini@pharmamar.com.

Abstract

We have defined the mechanism of action of lurbinectedin, a marine-derived drug exhibiting a potent antitumor activity across several cancer cell lines and tumor xenografts. This drug, currently undergoing clinical evaluation in ovarian, breast, and small cell lung cancer patients, inhibits the transcription process through (i) its binding to CG-rich sequences, mainly located around promoters of protein-coding genes; (ii) the irreversible stalling of elongating RNA polymerase II (Pol II) on the DNA template and its specific degradation by the ubiquitin/proteasome machinery; and (iii) the generation of DNA breaks and subsequent apoptosis. The finding that inhibition of Pol II phosphorylation prevents its degradation and the formation of DNA breaks after drug treatment underscores the connection between transcription elongation and DNA repair. Our results not only help to better understand the high specificity of this drug in cancer therapy but also improve our understanding of an important transcription regulation mechanism. Mol Cancer Ther; 15(10); 2399-412. ©2016 AACR.

PMID:
27630271
DOI:
10.1158/1535-7163.MCT-16-0172
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center